191 related articles for article (PubMed ID: 20235353)
1. [Role of renal anemia in progression of chronic kidney disease].
Racki S; Maleta I
Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
[TBL] [Abstract][Full Text] [Related]
2. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
[TBL] [Abstract][Full Text] [Related]
3. [Anemia as a risk factor for CKD and CVD].
Tsuruya K; Hirakata H
Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
[TBL] [Abstract][Full Text] [Related]
4. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
5. Anemia and cardiovascular risk in the patient with kidney disease.
Fishbane S
Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
[TBL] [Abstract][Full Text] [Related]
6. [Erythropoesis-stimulating agents: past, present and future].
Kes P; Basić-Jukić N
Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
[TBL] [Abstract][Full Text] [Related]
7. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
8. Anemia in renal disease: diagnosis and management.
Lankhorst CE; Wish JB
Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
[TBL] [Abstract][Full Text] [Related]
9. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
Moossavi S; Freedman BI
Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
[No Abstract] [Full Text] [Related]
10. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
11. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
12. Target hemoglobin level for EPO therapy in CKD.
Parfrey PS
Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
[No Abstract] [Full Text] [Related]
13. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Rossert J; Gassmann-Mayer C; Frei D; McClellan W
Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
[TBL] [Abstract][Full Text] [Related]
15. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
Singh AK; Hertello P
Nephrol Nurs J; 2005; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
[TBL] [Abstract][Full Text] [Related]
16. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
17. The role of erythropoiesis-stimulating agents in the treatment of anemia.
Fishbane S
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
[TBL] [Abstract][Full Text] [Related]
18. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
Coyne DW
Semin Dial; 2008; 21(3):212-6. PubMed ID: 18363603
[TBL] [Abstract][Full Text] [Related]
19. Anemia in CKD: prevalence, diagnosis, and treatment. Case study of the anemic patient.
Kammerer J; Ratican M; Elzein H; Mapes D
Nephrol Nurs J; 2002 Aug; 29(4):371-4. PubMed ID: 12224371
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.
Strippoli GF; Craig JC; Manno C; Schena FP
J Am Soc Nephrol; 2004 Dec; 15(12):3154-65. PubMed ID: 15579519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
